302 related articles for article (PubMed ID: 28138221)
1. Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.
Françoso A; Simioni PU
Drug Des Devel Ther; 2017; 11():177-184. PubMed ID: 28138221
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
3. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
4. Development of monoclonal antibodies for the treatment of colorectal cancer.
Goodin S
Am J Health Syst Pharm; 2008 Jun; 65(11 Suppl 4):S3-7; quiz S22-4. PubMed ID: 18499888
[TBL] [Abstract][Full Text] [Related]
5. The safety of monoclonal antibodies for treatment of colorectal cancer.
Berger MD; Lenz HJ
Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510
[TBL] [Abstract][Full Text] [Related]
6. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.
Mauri G; Pizzutilo EG; Amatu A; Bencardino K; Palmeri L; Bonazzina EF; Tosi F; Carlo Stella G; Burrafato G; Scaglione F; Marsoni S; Siravegna G; Bardelli A; Siena S; Sartore-Bianchi A
Cancer Treat Rev; 2019 Feb; 73():41-53. PubMed ID: 30616224
[TBL] [Abstract][Full Text] [Related]
7. Panitumumab a novel drug in cancer treatment.
Cartenì G; Fiorentino R; Vecchione L; Chiurazzi B; Battista C
Ann Oncol; 2007 Jun; 18 Suppl 6():vi16-21. PubMed ID: 17591813
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer.
Saoudi Gonzalez N; López D; Gómez D; Ros J; Baraibar I; Salva F; Tabernero J; Élez E
Expert Opin Drug Metab Toxicol; 2022 Nov; 18(11):755-767. PubMed ID: 36582117
[TBL] [Abstract][Full Text] [Related]
9. [Molecular target therapy and chemotherapy for advanced colorectal cancer].
Nakashima K; Yamazaki K; Boku N
Gan To Kagaku Ryoho; 2008 May; 35(5):725-30. PubMed ID: 18487907
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
11. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
Snyder LC; Astsaturov I; Weiner LM
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies in the treatment of advanced colorectal cancer.
Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
[TBL] [Abstract][Full Text] [Related]
14. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
Piront P; Van Daele D; Belaiche J; Polus M
Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
[TBL] [Abstract][Full Text] [Related]
15. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab.
Rivera F; Vega-Villegas ME; Lopez-Brea MF; Marquez R
Acta Oncol; 2008; 47(1):9-19. PubMed ID: 18097777
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies for targeted therapy in colorectal cancer.
Banerjee S; Flores-Rozas H
Cancer Biol Ther; 2010 Apr; 9(8):563-71. PubMed ID: 20200482
[TBL] [Abstract][Full Text] [Related]
17. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
18. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
19. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
You B; Chen EX
J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
[TBL] [Abstract][Full Text] [Related]
20. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]